Research suggests women using the contraceptive Depo-Provera for one year face a significantly higher risk of developing meningiomas [1].
This finding is critical for public health and medical practitioners because it identifies a potential link between a widely used hormonal contraceptive and the development of brain tumors. Understanding these risks allows patients and doctors to make more informed decisions regarding long-term birth control options.
Varun Kshettry, MD, an associate professor of neurosurgery at Cleveland Clinic, said the findings in reports and interviews. Kshettry specializes in skull-base, pituitary, and cerebrovascular surgery, as well as the treatment of trigeminal neuralgia [1, 2].
According to Kshettry, women who used depot medroxyprogesterone acetate, known as Depo-Provera, for just one year faced approximately five times the normal meningioma risk [1]. The data specifically associates this increased risk with a one-year duration of use [1].
While the risk multiplier is high, Kshettry noted the limitations of the current evidence. He said, "Unfortunately, at this point the data are still limited, but the signal is strong enough to warrant further investigation" [2].
The research aims to inform the medical community and the public about the potential health risks associated with this specific form of contraception [1]. Meningiomas are typically tumors that grow from the membranes surrounding the brain, and identifying triggers for their growth is a primary goal for neurosurgical research.
Kshettry operates out of the Cleveland Clinic in Cleveland, Ohio, where he continues to study the intersections of pharmaceutical use and neurological health [1, 2].
“Women who used depot medroxyprogesterone acetate (Depo-Provera) for just one year faced approximately five times the normal meningioma risk.”
The identification of a potential five-fold increase in meningioma risk associated with Depo-Provera suggests a need for more rigorous longitudinal studies. If confirmed, this could lead to updated clinical guidelines for the prescription of depot medroxyprogesterone acetate, particularly regarding the duration of use and the screening of patients for neurological symptoms.
